CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease

CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease

Abstract Inflammatory bowel disease (IBD) has emerged a global disease and the ascending incidence and prevalence is accompanied by elevated morbidity, mortality, and substantial healthcare system costs. However, the current typical one‐size‐fits‐all therapeutic approach is suboptimal for a substant...

Full description

Bibliographic Details
Main Authors: Wenbin Gong, Jiafei Yu, Tao Zheng, Peizhao Liu, Fan Zhao, Juanhan Liu, Zhiwu Hong, Huajian Ren, Guosheng Gu, Gefei Wang, Xiuwen Wu, Yun Zhao, Jianan Ren
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Clinical and Translational Medicine
Subjects:
CCL4
inflammatory bowel disease
piceatannol
Syk
Online Access:https://doi.org/10.1002/ctm2.339

Similar Items

Similar Items